Ongoing clinical trials, in regenerative therapy of patients suffering from myocardial infarctions, rely primarily upon administration of bone marrow stem cells to the infarcted zones. Unfortunately, low retention of these cells, to the therapeutic delivery sites, reduces effectiveness of this strategy; thus it has been identified as the most critical problem for advancement of cardiac regenerative medicine.Specific aims: The specific aim of this work was three-fold: (1) to isolate highly viable populations of human, autologous CD34+, CD117+, and CD133+ bone marrow stem cells; (2) to bioengineer heterospecific, tetravalent antibodies and to use them for recruiting of the stem cells to regenerated zones of infarcted myocardium; (3) to direct vasculogenesis of the retained stem cells with the defined factors.Patients methods: Cardiac tissue was biopsied from the hearts of the patients, who were receiving orthotopic heart transplants after multiple cardiac infarctions.
This tissue was used to engineer fully human in vitro models of infarcted myocardium. Bone marrow was acquired from these patients.
The marrow cells were sorted into populations of cells displaying CD34, CD117, and CD133. Heterospecific, tetravalent antibodies were bioengineered to bridge CD34, CD117, CD133 displayed on the stem cells with cardiac myosin of the infarcted myocardium.
The sorted stem cells were administered to the infarcted myocardium in the in vitro models.
Results:
Administration of the bioengineered, heterospecific antibodies preceding administration of the stem cells greatly improved the stem cells’recruitment and retention to the infarcted myocardium. Treatment of the retained stem cells with vascular endothelial growth factor and angiopoietin efficiently directed their differentiation into endothelial cells, which expressed vascular endothelial cadherin, platelet / endothelial cell adhesion molecule, claudin, and occludin, while forming tight and adherens junctions.
Conclusions:
This novel strategy improved retention of the patients’autologous bone marrow cells to the infarcted myocardium followed by directed vasculogenesis.
Therefore, it is worth pursuing it in support of the ongoing clinical trials of cardiac regenerative therapy.
Author: Marek MaleckiChelsea SaboEmily PutzerChris StampeAfsoon FooroharCarol QuachMichael BeauchaineXenia TombokanMark Anderson
Credits/Source: Molecular and Cellular Therapies 2013, 1:4
Published on: 2013-12-13
Tweet
News Provider: EUPB – European Press Bureau
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.